FDG-PET in follicular lymphoma management

Journal of Oncology

Volumn , Issue , 2012, Pages

  Bodet Milin, C ^a   Eugene T ^a   Gastinne, T ^a   Frampas, E ^a   Le Gouill, S ^a   Kraeber Bodere F ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; EPRATUZUMAB; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; YTTRIUM 90;

BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLICULAR LYMPHOMA; HUMAN; RADIOIMMUNOTHERAPY; RELAPSE; REVIEW; TREATMENT RESPONSE;

EID: 84864912355     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/370272     Document Type: Review

References (51)

1. Petrasch S., Stein H., Kosco M. H., Brittinger G., Follicular dendritic cells in non-Hodgkin lymphomas: localisation, characterisation and pathophysiological aspects European Journal of Cancer 1991 27 8 1052 1056
2. Horning S. J., Rosenberg S. A., The natural history of initially untreated low-grade non-Hodgkin's lymphomas New England Journal of Medicine 1984 311 23 1471 1475 (Pubitemid 15211022)
3. Bierman P. J., Natural history of follicular grade 3 non-Hodgkin's lymphoma Current Opinion in Oncology 2007 19 5 433 437 (Pubitemid 47356597)
4. Dreyling M., Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Annals of Oncology 2010 21 5 v181 v183
5. Solal-Céligny P., Roy P., Colombat P., White J., Armitage J. O., Arranz-Saez R., Au W. Y., Bellei M., Brice P., Caballero D., Coiffier B., Conde-Garcia E., Doyen C., Federico M., Fisher R. I., Garcia-Conde J. F., Guglielmi C., Hagenbeek A., Haoun C., LeBlanc M., Lister A. T., Lopez-Guillermo A., McLaughlin P., Milpied N., Morel P., Mounier N., Proctor S. J., Rohatiner A., Smith P., Soubeyran P., Tilly H., Vitolo U., Zinzani P.-L., Zucca E., Montserrat E., Follicular lymphoma international prognostic index Blood 2004 104 5, supplement 1258 1265 (Pubitemid 39166497)
6. Federico M., Bellei M., Marcheselli L., Luminari S., Lopez-Guillermo A., Vitolo U., Pro B., Pileri S., Pulsoni A., Soubeyran P., Cortelazzo S., Martinelli G., Martelli M., Rigacci L., Arcaini L., Di Raimondo F., Merli F., Sabattini E., McLaughlin P., Solal-Céligny P., Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project Journal of Clinical Oncology 2009 27 27 4555 4562
7. Juweid M. E., Stroobants S., Hoekstra O. S., Mottaghy F. M., Dietlein M., Guermazi A., Wiseman G. A., Kostakoglu L., Scheidhauer K., Buck A., Naumann R., Spaepen K., Hicks R. J., Weber W. A., Reske S. N., Schwaiger M., Schwartz L. H., Zijlstra J. M., Siegel B. A., Cheson B. D., Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma Journal of Clinical Oncology 2007 25 5 571 578 (Pubitemid 350002965)
8. Cheson B. D., Pfistner B., Juweid M. E., Gascoyne R. D., Specht L., Horning S. J., Coiffier B., Fisher R. I., Hagenbeek A., Zucca E., Rosen S. T., Stroobants S., Lister T. A., Hoppe R. T., Dreyling M., Tobinai K., Vose J. M., Connors J. M., Federico M., Diehl V., Revised response criteria for malignant lymphoma Journal of Clinical Oncology 2007 25 5 579 586 (Pubitemid 350002966)
9. Weiler-Sagie M., Bushelev O., Epelbaum R., Dann E. J., Haim N., Avivi I., Ben-Barak A., Ben-Arie Y., Bar-Shalom R., Israel O., 18 F-FDG avidity in lymphoma readdressed: a study of 766 patients Journal of Nuclear Medicine 2010 51 1 25 30
10. NCCN, Practice guidelines in oncology v.1.2010: non-Hodgkins Lymphomas. 2010
11. Pakos E. E., Fotopoulos A. D., Ioannidis J. P. A., 18 F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis Journal of Nuclear Medicine 2005 46 6 958 963 (Pubitemid 43733510)
12. Blum R. H., Seymour J. F., Wirth A., MacManus M., Hicks R. J., Frequent impact of [ 18 F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma Clinical Lymphoma 2003 4 1 43 49 (Pubitemid 36826876)
13. Janikova A., Bolcak K., Pavlik T., Mayer J., Kral Z., Value of [ 18 F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clinical Lymphoma and Myeloma 2008 8 5 287 293
14. Whrer S., Jaeger U., Kletter K., Becherer A., Hauswirth A., Turetschek K., Raderer M., Hoffmann M., 18 F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading Annals of Oncology 2006 17 5 780 784
15. Jerusalem G., Beguin Y., Najjar F., Hustinx R., Fassotte M. F., Rigo P., Fillet G., Positron emission tomography (PET) with 18 F-fluorodeoxyglucose (18 F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL) Annals of Oncology 2001 12 6 825 830 (Pubitemid 32655093)
16. Karam M., Novak L., Cyriac J., Ali A., Nazeer T., Nugent F., Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas Cancer 2006 107 1 175 183 (Pubitemid 43939045)
17. Scott A. M., Gunawardana D. H., Wong J., Kirkwood I., Hicks R. J., Ho Shon I., Ramshaw J. E., Robins P., Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study European Journal of Nuclear Medicine and Molecular Imaging 2009 36 3 347 353
18. Wirth A., Foo M., Seymour J. F., MacManus M. P., Hicks R. J., Impact of [ 18 F] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular Non-Hodgkin lymphoma International Journal of Radiation Oncology Biology Physics 2008 71 1 213 219
19. Bishu S., Quigley J. M., Bishu S. R., Olsasky S. M., Stem R. A., Shostrom V. K., Holdeman K. P., Paknikar S., Armitage J. O., Hankins J. H., Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma Leukemia and Lymphoma 2007 48 8 1548 1555 (Pubitemid 47272805)
20. Le Dortz L., De Guibert S., Bayat S., Devillers A., Houot R., Rolland Y., Cuggia M., Le Jeune F., Bahri H., Barge M. L., Lamy T., Garin E., Diagnostic and prognostic impact of 18 F-FDG PET/CT in follicular lymphoma European Journal of Nuclear Medicine and Molecular Imaging 2010 37 12 2307 2314
21. Giné E., Montoto S., Bosch F., Arenillas L., Mercadal S., Villamor N., Martnez A., Colomo L., Campo E., Montserrat E., Lpez-Guillermo A., The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma Annals of Oncology 2006 17 10 1539 1545 (Pubitemid 44542041)
22. Yuen A. R., Kamel O. W., Halpern J., Horning S. J., Long-term survival after histologic transformation of low-grade follicular lymphoma Journal of Clinical Oncology 1995 13 7 1726 1733
23. Schder H., Noy A., Gnen M., Weng L., Green D., Erdi Y. E., Larson S. M., Yeung H. W. D., Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma Journal of Clinical Oncology 2005 23 21 4643 4651 (Pubitemid 46224066)
24. Bodet-Milin C., Kraeber-Bodéré F., Moreau P., Campion L., Dupas B., Le Gouill S., Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma Haematologica 2008 93 3 471 472 (Pubitemid 351398655)
25. Tang B., Malysz J., Douglas-Nikitin V., Zekman R., Wong R. H., Jaiyesimi I., Wong C. Y. O., Correlating metabolic activity with cellular proliferation in follicular lymphomas Molecular Imaging and Biology 2009 11 5 296 302
26. Noy A., Schder H., Gnen M., Weissler M., Ertelt K., Cohler C., Portlock C., Hamlin P., Yeung H. W. D., The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL) Annals of Oncology 2009 20 3 508 512
27. Wahl R. L., Jacene H., Kasamon Y., Lodge M. A., From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors Journal of Nuclear Medicine 2009 50 1, supplement 122S 150S
28. Cheebsumon P., Yaqub M., Van Velden F. H. P., Hoekstra O. S., Lammertsma A. A., Boellaard R., Impact of [ 18 F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology European Journal of Nuclear Medicine and Molecular Imaging 2011 38 12 2136 2144
29. Terasawa T., Nihashi T., Hotta T., Nagai H., 18 F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: a systematic review Journal of Nuclear Medicine 2008 49 1 13 21
30. Zijlstra J. M., Lindauer-Van Der Werf G., Hoekstra O. S., Hooft L., Riphagen I. I., Huijgens P. C., 18 F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review Haematologica 2006 91 4 522 529
31. Juweid M. E., Wiseman G. A., Vose J. M., Ritchie J. M., Menda Y., Wooldridge J. E., Mottaghy F. M., Rohren E. M., Blumstein N. M., Stolpen A., Link B. K., Reske S. N., Graham M. M., Cheson B. D., Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography Journal of Clinical Oncology 2005 23 21 4652 4661 (Pubitemid 46224067)
32. Lopci E., Zanoni L., Chiti A., Fonti C., Santi I., Zinzani P. L., Fanti S., FDG PET/CT predictive role in follicular lymphoma European Journal of Nuclear Medicine and Molecular Imaging 2012 39 5 864 871
33. Trotman J., Fournier M., Lamy T., Seymour J. F., Sonet A., Janikova A., Shpilberg O., Gyan E., Tilly H., Estell J., Forsyth C., Decaudin D., Fabiani B., Gabarre J., Salles B., Van Den Neste E., Canioni D., Garin E., Fulham M., Borght T. V., Salles G., Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants Journal of Clinical Oncology 2011 29 23 3194 3200
34. Lopci E., Santi I., Derenzini E., Fonti C., Savelli G., Bertagna F., Bell M., Botto B., Huglo D., Morschhauser F., Zinzani P., Fanti S., FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study Annals of Oncology 2010 21 9 1877 1883
35. Bodet-Milin C., Kraeber-Bodéré F., Dupas B., Morschhauser F., Gastinne T., Le Gouill S., Campion L., Harousseau J. L., Wegener W. A., Goldenberg D. M., Huglo D., Evaluation of response to fractionated radioimmunotherapy with 90 Y-epratuzumab in non-Hodgkin's lymphoma by 18 F- fluorodeoxyglucose positron emission tomography Haematologica 2008 93 3 390 397 (Pubitemid 351398640)
36. Terasawa T., Lau J., Bardet S., Couturier O., Hotta T., Hutchings M., Nihashi T., Nagai H., Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review Journal of Clinical Oncology 2009 27 11 1906 1914
37. Itti E., Lin C., Dupuis J., Paone G., Capacchione D., Rahmouni A., Haioun C., Meignan M., Prognostic value of interim 18 F-FDG PETin patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy Journal of Nuclear Medicine 2009 50 4 527 533
38. Horning S. J., Juweid M. E., Schder H., Wiseman G., McMillan A., Swinnen L. J., Advani R., Gascoyne R., Quon A., Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Blood 2010 115 4 775 777
39. Zinzani P. L., Gandolfi L., Broccoli A., Argnani L., Fanti S., Pellegrini C., Stefoni V., Derenzini E., Quirini F., Baccarani M., Midtreatment 18 F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma Cancer 2011 117 5 1010 1018
40. Casasnovas R. O., Meignan M., Berriolo-Riedinger A., Bardet S., Julian A., Thieblemont C., Vera P., Bologna S., Brire J., Jais J. P., Haioun C., Coiffier B., Morschhauser F., SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma Blood 2011 118 1 37 43
41. Safar V., Dupuis J., Itti E., Jardin F., Fruchart C., Bardet S., Véra P., Copie-Bergman C., Rahmouni A., Tilly H., Meignan M., Haioun C., Interim [ 18 F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab Journal of Clinical Oncology 2012 30 2 184 190
42. Zinzani P. L., Rigacci L., Stefoni V., Broccoli A., Puccini B., Castagnoli A., Vaggelli L., Zanoni L., Argnani L., Baccarani M., Fanti S., Early interim 18 F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients European Journal of Nuclear Medicine and Molecular Imaging 2012 39 1 4 12
43. Markova J., Kahraman D., Kobe C., Skopalova M., Mocikova H., Klaskova K., Dedeckova K., Eich H.-T., Bll B., Dietlein M., Kozak T., Role of [ 18 F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone Leukemia and Lymphoma 2012 53 1 64 70
44. Gallamini A., Patti C., Viviani S., Rossi A., Fiore F., Di Raimondo F., Cantonetti M., Stelitano C., Feldman T., Gavarotti P., Sorasio R., Mul A., Leone M., Rambaldi A., Biggi A., Barrington S., Fallanca F., Ficola U., Chauvie S., Gianni A. M., Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses British Journal of Haematology 2011 152 5 551 560
45. Cerci J. J., Pracchia L. F., Linardi C. C. G., Pitella F. A., Delbeke D., Izaki M., Trindade E., Soares J., Buccheri V., Meneghetti J. C., 18 F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma Journal of Nuclear Medicine 2010 51 9 1337 1343
46. Perk L. R., Visser O. J., Stigter-Van Walsum M., Vosjan M. J. W. D., Visser G. W. M., Zijlstra J. M., Huijgens P. C., Van Dongen G. A. M. S., Preparation and evaluation of 89 Zr-Zevalin for monitoring of 90 Y-Zevalin biodistribution with positron emission tomography European Journal of Nuclear Medicine and Molecular Imaging 2006 33 11 1337 1345 (Pubitemid 44630790)
47. Van Dongen G. A., Poot A. J., Vugts D. J., PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET Tumor Biology 2012 33 3 607 615
48. Rizvi S. N. F., Visser O. J., Vosjan M. J. W. D., Van Lingen A., Hoekstra O. S., Zijlstra J. M., Huijgens P. C., Van Dongen G. A. M. S., Lubberink M., Biodistribution, radiation dosimetry and scouting of 90 Y- ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89 Zr-ibritumomab tiuxetan and PET European Journal of Nuclear Medicine and Molecular Imaging 2012 39 3 512 520
49. Divgi C. R., Pandit-Taskar N., Jungbluth A. A., Reuter V. E., Gnen M., Ruan S., Pierre C., Nagel A., Pryma D. A., Humm J., Larson S. M., Old L. J., Russo P., Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial Lancet Oncology 2007 8 4 304 310 (Pubitemid 46464522)
50. Brjesson P. K. E., Jauw Y. W. S., Boellaard R., De Bree R., Comans E. F. I., Roos J. C., Castelijns J. A., Vosjan M. J. W. D., Kummer J. A., Leemans C. R., Lammertsma A. A., Van Dongen G. A. M. S., Performance of immunopositron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients Clinical Cancer Research 2006 12 7 I 2133 2140
51. Dijkers E. C. F., Kosterink J. G. W., Rademaker A. P., Perk L. R., Van Dongen G. A. M. S., Bart J., De Jong J. R., De Vries E. G. E., Lub-de Hooge M. N., Development and characterization of clinical-grade 89 Zr- trastuzumab for HER2/neu immunoPET imaging Journal of Nuclear Medicine 2009 50 6 974 981